Page 1
6/5/2018
1
DMT UPDATE
Practical help to
DMT management in MS Regional MS Summit 2018
A Wundes, MD
Medical Director Neurology
UW MS Center
University of Washington, Seattle, WA
DISCLAIMER
Research funding: Biogen, Alkermes
Handout of 2017 talk is in your package: Comprehensive practical guide to
DMT decision making reviewing all drugs
Not a comprehensive review
Not equal weight to all drugs
Page 2
6/5/2018
2
OBJECTIVES
• Review AAN DMT guidelines
• Learn about the 2017 /2018 DMT updates
• Case-based examples of DMT decision making
Rae-Grant et al. Neurology 2018:90:777-788
Page 3
6/5/2018
3
AAN DMT Practice Guidelines
Recommendations
• 17 on starting DMT
• 10 on switching DMT for breakthrough dz
• 3 on stopping DMT
A = “must”
B = “should”
C = “may”
Neurology 2018;90:777-788
4x “MUST” Clinicians must…
1. Ascertain and incorporate patients’ preferences re safety, route of administration, lifestyle, cost, efficacy, common AE and tolerability in choice of DMT
2. Engage in an ongoing dialogue re treatment decisions throughout the disease course
3. Counsel patients on DMTs to notify providers of new or worsening symptoms
4. Counsel that there is an increased risk of relapse or MRI dz activity within 6 months of D/C natalizumab
Page 4
6/5/2018
4
Starting DMT “SHOULD”
• Discuss & if interested prescribe DMT for CIS if ≥2 brain lesions
• Prescribe alemtuzumab, fingolimod or natalizumab if highly active
• Not prescribe mitoxantrone unless benefits greatly outweigh risks
• Offer ocrelizumab to PPMS “who are likely to benefit unless risks outweigh benefits”
• Monitor adherence, AE, tolerability, safety and effectiveness; should follow pt at least annually or per REMS
“MAY”
• Recommend serial MRI at least annually 1st 5 years and close follow up rather than DMT for CIS/RRMS not on DMT and stable x2y
• Initiate NTZ only if reasonable chance benefit if JCV ab pos >0.9
• Direct to financial support programs or recommend AZA/cladribine
“SHOULD”
• Monitor MRI
• Discuss switch if 1 or more relapses or, 2 or more unequivocal new MRI lesions or increased disability over 1 year period - if long enough on and adherent to DMT
• Discuss oral or less frequent injectable DMT if intolerable AE or injection fatigue
• Discuss undefined malignancy and infection risk with newer DMTs without long-term safety data
• Switch to alternative DMT if on NTZ and JCV ab pos, esp if >0.9
• Check NTZ antibodies if infusion reactions or break through dz
Switching DMT
Page 5
6/5/2018
5
Stopping DMT “SHOULD”
• Advocate for MS patients who are stable on DMT to continue their current DMT unless D/C DMT trial warranted
• Counsel pts who are stable and want to stop DMT for need for ongoing FU and periodic re-evaluation D/C DMT
• Assess likelihood of future relapse in SPMS d/t age, dz duration, relapse hx and MRI activity
“MAY” advise D/C DMT SPMS w/o relapse or gd+ lesion and not ambulatory for at least 2 years
• Review risk of continuation vs D/C DMT in CIS who have not progressed to MS
“Real life case”
• 44yo male engineer with outside dx MS
• My assessment CIS rather than MS
• Partial TM 2011 sensory sx, Lhermitte gd+ C2-3 lesion
• Brain MRI minimal WM changes
• CSF results?
• PMH: Low Vit D, HLP, BMI 34, MVA 2015
• No dz activity while on glatiramer acetate x 7 years
Page 6
6/5/2018
6
A. Treatment success, should stay on DMT
B. Counsel could consider DMT D/C trial
C. Stop DMT b/o did not progress to MS
AAN Patient DMT Guide
Find a copy of the AAN Patient Guide included in your materials
Page 7
6/5/2018
7
DISEASE MODIFYING THERAPIES
2017-2018 UPDATES
Glatiramer Acetate
• Now 2 generics available
– Glatopa®
– Mylan®
• Both available in daily 20 mg and 40 mg TIW formulations
Page 8
6/5/2018
8
Daclizumab/Zinbryta®
• Voluntarily withdrawn from market 3/2018 for safety concerns: 12x brain infections
Oral agents
Page 9
6/5/2018
9
Fingolimod / Gilenya®
• Once daily po 0.5 mg
• FDA approved in 2010
• 231,000+ patients to date (536K PY)
Spingosine-1-phosphate receptor modulator Prevents egress of lymphocytes from lymph nodes
Fingolimod-related PML
• Exposure: 231,000
• PML cases: n=19 (excluding cases NTZ ≤6m PML dx)
• Risk factors: Treatment duration
1:5,000 if rx >2 years (18/94K)
<1:10,000 overall
• PI update:
– Most cases in pts > 2 years rx
– Some cases dx’ed by MRI while initially asymptomatic
Novartis Medical Information Service, PI update 12/2017
Page 10
6/5/2018
10
Report of 15 PML cases as of August 2017
• Mean age 53 (n=5 <50yo), MS duration 4-35 years
• 14/15 clinical sx whereas 1 identified d/t MRI findings
• 2/15 possible confounders: prior cancer, prior IS for UC
• 4/14 ALC ≤ 0.2
• 3 deaths, others deficits aphasia, mobility, cognition
Fingolimod-related PML
• No specific clinical features or guidelines at this point
• Lymphocyte counts and subsets appear not associated
• Challenge of weighing PML risk vs possibly inappropriate modification of effective MS treatment
• Patient, provider and staff education and vigilance
– Importance of clinical and MRI surveillance
– Stop drug immediately if concerns for PML
– PML sx can resemble MS relapse but tend to be slowly and persistently progressive
– Red flags clinically: subacute cognitive, language, seizures
Page 11
6/5/2018
11
26yo M engineer
• ON age 12 (his mom dx’ed with MS 1y earlier)
• ON age 18
• Overall thus far favorable clinical course, EDSS 1
• IFNb-1a sc (Rebif®) x 1.5 years, d/c “pill easier”
• FGL since 2015
53yo Female • MS x 15 y
• Established care 2013 while on FGL x 1 year
• Prior DMT
– IFNb-1a (Rebif®) x 2 y, D/C “relapses” q3m, stress high
– NTZ (Tysabri®) x 36 inf, D/C after JCV ab conversion
• Main sx mood, pain, fatigue, some imbalance
Page 12
6/5/2018
12
Chengde Pham et al. BMJ Case Reports 2017
Initial
• 61yo on FGL x 3y, previously D/C NTZ d/t JCV ab +
• HA/neck pain (coughing ), N, vertigo, 10 kg WL x 2wk
• R beat nystagmus, quickly became confused
• MRI extensive PF leptomeningeal nodular enhancement, edema w/ mass effect and early cerebellar tonsillar herniation
• CSF via external ventricle drain Cryptococcus +
• Antifungal iv/po, D/C FGL, VP shunt
• MRI improved at 6 wks but new UI and new MRI lesions bifrontal, ?fungal, ?IRIS, ?MS, iv/po steroids 6 wk
Initial
Cryptococcus meningitis
• Overall risk 0.11/100 PY in post-marketing setting
• More cases than PML cases
• Unlike PML, any age group (27-68yo)
• Usually after longer FGL exposure (16 m – 5 years)
• 1/3 without meningeal sx
Novartis Medical Information Services
Page 13
6/5/2018
13
PI Updates – Infections / Cancer
Serious and life-threatening infections have occurred
• Varicella zoster, herpes simplex and cryptococcus infections incl fatal meningitis, encephalitis and disseminated infections
• Consider when atypical MS relapse and organ failure
Increased risk basal cell cancer and melanoma
• Vigilance skin lesions
• PI recommends advising pts to use sun protection
PI update 12/2017 + 5/2018
PI Updates – Bradycardia 1st dose
• Max decrease usually within 1st 6h, usually asymptomatic and recovers, though not baseline 8-10h
• D/t physiological diurnal rhythm 2nd period HR w/i 24h
• Pre-existing ischemic heart dz, h/o MI, CHF, CVA, uncontrolled HTN, recurrent syncope, severe untreated OSA
Evaluate by cardiologist before FDO
Overnight continuous ECG monitoring
• Transient similar but to lesser reduction HR following dosing in 1st 2-4 weeks
PI update 5/2018
Page 14
6/5/2018
14
Pediatric MS
PI Updates
• RRMS patients age 10 or older
• Recommended all vaccinations per guidelines before FGL
• If ≤40 kg: 0.25 mg once daily
• Pediatrics pts ≥10y + ≥40kg: 0.5 mg once daily 82% reduction AAR1
53% reduction new T2 lesions1
66% reduction gd+ lesions1
Ongoing open-label study
Chitnis et al. ECTRIMS 2017; manuscript under review. PI update 5/2018
Baseline labs with VZV status and if needed VZV vaccination before starting agent
Pay attention to co-medications and co-morbidities - DM, uveitis risk of ME↑ - Co-meds HR↓
Lymphopenia not associated with infections
Risk of opportunistic infections
Increased PML rate after 2 years of treatment
Fingolimod: Clinical Pearls
oral 0.5 once daily Gilenya®
Page 15
6/5/2018
15
Teriflunomide/Aubagio®
Once daily po – 7 vs 14 mg
FDA approved in 2012 for RRMS and CIS
84,000 patients to date (162K PY)
Closely related to leflunomide (for RA)
Blocks de novo pyrimidine synthesis
→ cytostatic effect on proliferating T and B cells
1 PML Case on Teriflunomide
Due to teriflunomide vs carry-over from natalizumab?
Some PML cases reported on leflunomide1
Stopped NTZ #33
JCV ab pos index 3.6
EDSS 1.0
MRI @ 6wk stable
DMT hiatus x 5+m
Started TFL
R-sided weakness, aphasia @ 10 wk
EDSS 3.5
MRI suspicious PML
CSF JCV DNA+
11 copies/ml
(false-positive?)
Chelation therapy
Clinical and MRI progression
PML-IRIS suspected; 3 day IVMP
Eventually improvement, EDSS 1.0
Started on GA
Lorefice et al, Neurology 2018:90:1-3. 1 FAERS: n=24, Sanofi n=7 PML in RA with prior IS
Page 16
6/5/2018
16
• 54yo black woman dx’ed with follicular lymphoma
• Teriflunomide x 8 months
• No RF other than age
• Per Authors
– 50-54yo: 7 FL /100,000
– 10 cases on teriflunomide*
– 82 cases on leflunomide*
Landais et al, Mult Scler Rel Dis 2017;17:92-94 (*VegiBase: WHO global database AE reports)
Lymphoma on Teriflunomide
• Hypersensitivity/skin pooled clinical trials: 16.1% vs 14.3% plc1
• Severe skin reactions reported – 7x Steven Johnson Syndrome in post-market setting2
– 84x skin exfoliation in post-market setting2
– 1 fatal TEN report in post-market setting3
1 Leist et al. Pooled safety data 4 clinical studies (n=3044) AAN 2014, 2 FAERS, 3 Gerschenfeld. MS Journal 2015
46y F
MS x 10y
IFN, DMF dc’ed for tolerability
Teriflunomide
Day 19 transient FLS x 5 days
Day 28 fever, asthenia, D/C drug
Day 30 respiratory failure
Day 34 TEN suspected
Day 39 death
Teriflunomide: Skin Reactions
Page 17
6/5/2018
17
Teriflunomide: Clinical Pearls oral 7 or 14 mg once daily Aubagio®
Pregnancy category X (need reliable contraception)
Rule out latent TB
Monthly LFT monitoring x6 months
Monitor CBCdiff
Risk of serious skin reactions
Expedited elimination protocol if needed
Dimethyl fumarate / Tecfidera®
• Orally 240 mg twice daily
• FDA approved in 2013
• 311,000+ patients to date (544+K PY)
• Activates nuclear factor 2 (Nrf2) pathway; response to oxidative stress
• Th1 → Th2 shift
Page 18
6/5/2018
18
DMF-related PML
• Exposure: 311,000
• PML cases: n=5
• Risk factors: Prolonged lymphopenia, age
• PI updates:
– Majority of PML cases ALC <0.5, some <0.8
– In other MS drugs some cases of early PML dx based on MRI findings in asymptomatic pts, usually better outcome
Biogen Medical Information Service, PI update 12/2017
• 1 death, other survival but no specifics available • Low CSF JCV viral copies: 2x 12 ultrasensitive JCV PCR!
DMF-related PML Cases
Page 19
6/5/2018
19
DMF-induced Lymphopenia
Mean ALC↓ by 30% in 1st y
and stabilized above LLN
9.4% Mod (0.5 - <0.8) 2.1% Severe (<0.5)
ALC in 1st year predictive for severe, prolonged lymphopenia
Fox et al. Pooled safety data 4 clinical studies (ph II, 2 ph III, extension; n=2512, K PY) ECTRIMS 2017
• All ALC >0.8 in 1st year 0.1%
• ALC <0.8 in 1st year 12%
• ALC <0.5 in 1st year 51%
Strong correlation of ALC with CD4 and CD8 subsets
Recovery Lymphopenia after D/C
After D/C
6 months after D/C with severe, prolonged lymphopenia (n=34)
At least 1x ALC >0.8: 41%
At least 1x ALC >LLN: 24%
Severe, prolonged lymphopenia on DMF Moderate, prolonged lymphopenia on DMF
Fox et al. Pooled safety data 4 clinical studies (ph II, 2 ph III, extension; n=2512, K PY) ECTRIMS 2017
Page 20
6/5/2018
20
Slower taper may help with side effects
Montelukast (Singulair) for GI side effects
Aspirin or anti-histamine for flushing
Monitor lymphocyte counts and LFT
Rare PML cases
Dimethyl fumarate: Clinical Pearls
oral 240 mg twice daily Tecfidera®
Infusions
Page 21
6/5/2018
21
Natalizumab / Tysabri®
• Once monthly infusion
• FDA approved in 2006
• REMS program required (TOUCH)
• 181,300 patients to date
Monoclonal antibody to α 4 integrin = VLA-4 Prevents extravasation of T-cells and monocytes into CNS
“Real life case” 35 yo AA male professional
• Natalizumab since 2012
• Past glatiramer acetate x 3y, D/C for ISR, 1 relapse, MRI
• JCV ab 1x POS 0.45 in 2/2013, then 12x neg by 11/2015
• EDSS 2.0
4/2018 re-established care after 2.5 y hiatus d/t insurance
• Last MRI 5/2015
• JCV ab tested x3, remained negative
Safety monitoring up to date?
Page 22
6/5/2018
22
• Exposure: 181,300 (638K PY)
• PML cases: n=763 in MS (Crohn’s n=3)
• Risk factors
– JCV antibody status
– Prior immunosuppression
– Natalizumab treatment duration
• PI update 4/2018 JCV antibody index
Natalizumab-related PML
Biogen Safety Update March 2018
PML risk algorithm
Koendgen Biogen ECTRIMS 2016
Wait 2 weeks after PLEX to avoid false-neg result
Wait 6 months after IVIG to avoid false-pos result
Page 23
6/5/2018
23
PML risk algorithm
1:10,000 - regardless of rx duration and prior use of IS 5 PML cases worldwide reported
Koendgen Biogen ECTRIMS 2016
Wait 2 weeks after PLEX to avoid false-neg result
Wait 6 months after IVIG to avoid false-pos result
PML risk algorithm
1: 5,000 1: 325 Koendgen Biogen ECTRIMS 2016
Wait 2 weeks after PLEX to avoid false-neg result
Wait 6 months after IVIG to avoid false-pos result
Page 24
6/5/2018
24
PML risk algorithm
• Highest PML risk ! • JCV ab index does
not apply!
1: 3,333
1: 120
Koendgen Biogen ECTRIMS 2016
Wait 2 weeks after PLEX to avoid false-neg result
Wait 6 months after IVIG to avoid false-pos result
• TOUCH data as of 6/1/2017
• Included JCV ab positive patients only
• SID (standard interval): average dosing ≥3 and <5 wk
• EID (extended interval): average dosing >5 and ≤12 wk
• NO info available re JCV ab index or efficacy data!
Zhovtis, ACTRIMS 2018 platform
Page 25
6/5/2018
25
Baseline demographics all groups:
• Age 43-44
• 5-6% prior IS
• EID: slightly higher total # and duration NTZ
94%
risk
88%
risk
Zhovtis, ACTRIMS 2018 platform & Zhovtis ACTRIMS + AAN 2018 poster
• Most EID pts switched from SID after >2 years treatment
• Relative small dosing interval; average EID 35-43 days vs SID 30-31 days
• No efficacy data available
Page 26
6/5/2018
26
Personalized NTZ dosing?
John Foley, AAN 2018 poster
NTZ concentration varied 100-fold
Mean concentration lower in EID
NTZ concentration affected by cycle
length and body weight (BMI↓, conc ↑)
Retrospective chart review (6m):
self-reported relapse and MRI change
without difference EID vs SID
Single PML case in this cohort:
Particularly high concentration (low BMI)
JCV infection of granule cell neurons in the cerebellum
• AKA JC virus granule cell neuronopathy [JCV GCN]
• Cerebellar dfct: ataxia, incoordination, apraxia, visual sx
• MRI: cerebellar atrophy
• DX: MRI w/wo, CSF for JC viral DNA
• Distinct from PML but can occur with and without PML
• Should be managed similarly to PML
Tysabri® PI; Koralnik Ann Neurology 2005
Page 27
6/5/2018
27
Acute retinal necrosis (ARN): • Fulminant viral infection of retina
• Decreased visual acuity, redness, or eye pain
• Refer PROMPTLY for retinal screening for ARN
• Some cases occurred with CNS herpes meningitis /encephalitis
• Serious cases of ARN led to blindness of one or both eyes
• Following ARN, consider discontinuation of TYSABRI
Immunosuppression/infections: • <1% pt with opportunistic infections:
• Pulmonary mycobacterium avium intracellulare, aspergilloma, cryptococcal fungemia and meningitis, candida pneumonia
Additional PI Updates Natalizumab
Tysabri ® PI
Natalizumab: Clinical Pearls iv once monthly Tysabri®
Check JCV antibody in blood regularly
Check brain MRI regularly
Any new neurologic symptom or new MRI
lesion on natalizumab is concerning for PML
Concerns for reactivation and rebound MS
disease activity when stopping drug
Page 28
6/5/2018
28
Ocrelizumab / Ocrevus®
• Infusion q6 months
• FDA approved March 2017 for RRMS and PPMS
• Total exposure n= 40,000+ (15+K PY)
Monoclonal antibody to CD20 on B lymphocytes B cell depletion
Bar-Or AAN 2018
Page 29
6/5/2018
29
Open-label extension RRMS trials
OCR / OCR
IFN / OCR
OCR / OCR
IFN / OCR
Change EDSS from baseline
Open label extension Double blind
Open label extension Double blind
Time to onset to Confirmed Disability Improvement
Immature data
Hauser et al.
AAN 2018
Time to cognitive decline Pooled RRMS phase III trials
Patients on OCR had significantly lower risk (HR 0.6) of sustained cognitive decline at 12 and 24 wks compared to pts on IFN
- mITT cohort; both 4% and 10% SDMT cut off
- Pts at risk of progression (EDSS 4.0)2
- similar trend in patients with baseline cognitive difficulties
Cohen et al. Platform AAN 2018 , 2: Benedict at al. Poster AAN 2018
Page 30
6/5/2018
30
Infection and PML risk
• Some increase URI, LRI, skin and herpes infections
• To date 1 opportunistic infections (systemic Pasteurella infection), none in trials
• Hepatitis B reactivation warning (anti-CD20 rx)
• Boxed warning PML
– To date no PML cases d/t OCR
– 3 carry-over PML cases (NTZ, fingolimod)
– RTX approved 1997 for NHL, CLL, RA, PA, >4 million pt PML not only in hematological malignancies but also RA n=9, SLE n=12, MS n=1; est risk in RA 1:20,000+
Hauser et al. AAN 2018, Borie Semin Arthritis Rheum 2015
Vaccinations
• Recommendation to complete vaccines 6 week BEFORE
• No live vaccines while on OCR
• Antibodies against common viral/bacterial antigens were maintained x 2 years in pivotal trials
Responses to vaccines while fully B-cell depleted by ocrelizumab
Bar-Or et al. AAN 2018
Tetanus 23-PPV Influenza
Page 31
6/5/2018
31
In phase III trials more malignancies in OCR compared to control groups (IFN, PLC), primarily breast CA
Thus far incidence rates malignancies and breast cancer remain within range of epidemiologic background
Appears that comparator groups lower than expected incidences
Malignancies
Any malignancy per 100 PY compared to Danish MS registry Breast CA OCR vs 3 MS registries
Hauser et al. Platform presentation AAN 2018
Deaths
• 40+K pts treated to date
• Incidence of fatalities 4/2017 – 3/2018: 0.28 per 100 PY
• No obvious pattern reported
If interested, detailed information included as supplemental slides
Phase 3
OPERA I/II
trials*
Phase 3
ORATORIO
trial*
All OCR
MS clinical
trials†
Post-
marketing
setting‡
French cohort
study
(n=27+K)
US retrosp
study
(n=30K)
Incidence rate
per 100-PY
0.07 0.25 0.169 0.2806 0.37 0.9
0.73 PMS
0.32 RRMS
Genentech Medical Information Services May 2018
Page 32
6/5/2018
32
Ocrelizumab: Clinical Pearls iv once every 6 months Ocrevus®
Infusion reactions: premedication, slow titration
Hepatitis B testing required
Consider more extensive baseline lab screening
Consider pneumonia/Hep B vaccination
UW Medicine MS Center Located on NWH campus
1536 N 115th St
Seattle, WA 98133
Phone: 206.598.3344
Page 33
6/5/2018
33
© 2018 Genentech, Inc. All rights reserved.
Post-marketing experience: PML
As of April 2018, we have confirmed 3 carry-over cases of PML in MS patients treated with
ocrelizumab1
■ The first case (May 2017) was from a compassionate-use program in an anti-JCV-
positive patient who was switched to ocrelizumab after 36 infusions of
natalizumab.2 Assessment of the information resulted in the case being reported to
regulators as related to natalizumab and not ocrelizumab.
■ The second case (April 2018), occurred in a patient who had increasingly worsening
neurological symptoms and MRI changes prior to discontinuing treatment with
fingolimod in December 2017. The patient started treatment with ocrelizumab in
March/April 2018. In April 2018, MRI changes, worsening clinical presentation, and
JCV DNA in the CSF confirmed the diagnosis of PML. The case was reported to
regulators as a carry-over PML from fingolimod as assessed by the physician3
■ The third case (April 2018) occurred in a JCV+ patient who was previously treated with
natalizumab for 7 years. Due to MRI changes and worsening clinical symptoms,
natalizumab was discontinued in February 2018. The patient received a single infusion
of ocrelizumab in April 2018. The case was reported by the physician as a carry-over
PML from natalizumab3
■ As described in the prescribing information, PML remains an important potential risk4
JCV=John Cunningham virus; MS=multiple sclerosis; PML=progressive multifocal leukoencephalopathy.
1. Hauser SL, et al. Presented at: AAN Meeting 2018 (Platform presentation ( S36.001) 2. Hauser SL, et al. Presented at: 7th Joint ECTRIMS-ACTRIMS Meeting 2017 (Poster P676). 3. Genentech, data on file. 4. Ocrevus® [prescribing information]. South San Francisco, CA: Genentech, Inc, a Member of the Roche Group; March 2017.
© 2018 Genentech, Inc. All rights reserved.
Fatalities summary: Phase 2 and Phase 3 clinical trials (controlled treatment period)
As of January 2016, eight fatalities occurred in the OCR groups and five fatalities occurred in the control
groups
■ OPERA I and II studies, controlled treatment period
• One fatality occurred in the OCR group (completed suicide) and two fatalities in the IFN β-1a group
(completed suicide, mechanical ileus)
■ ORATORIO study, controlled treatment period
• Four fatalities occurred in the OCR group (pneumonia, pulmonary embolism, aspiration pneumonia,
metastatic pancreatic cancer) and three fatalities in the placebo group (traffic accident, aspiration
pneumonia, sudden cardiac death)
■ Phase 2 study
• Among three fatalities in the OCR group, one occurred during the controlled treatment period (systemic
inflammatory response syndrome) and two (unknown cause, injury) during the safety follow-up, more
than 1 year after the final dose of OCR
■ There was no increase in fatalities in OCR-treated patients versus controls in the clinical trials
66
OPERA (pooled)* ORATORIO†
IFN β-1a
incidence rate‡
(95% CI)
OCR
incidence rate‡
(95% CI)
Placebo
incidence rate‡
(95% CI)
OCR
incidence rate‡
(95% CI)
OCR controlled
treatment period 0.14 (0.02, 0.52) 0.07 (0, 0.38) 0.41 (0.08, 1.20) 0.25 (0.07, 0.64)
*Two identical Phase 3, global, randomized, double-blind, double-dummy studies with a 96-week controlled period during which 1,656 patients with relapsing forms of MS received either
intravenous OCR (600 mg) every 24 weeks or subcutaneous IFN β-1a (44 μg) three times weekly.†A Phase 3, global, randomized, double-blind study with a ≥120-week controlled period
during which 732 patients with primary progressive MS received either intravenous OCR (600 mg) or placebo every 24 weeks (2:1 randomization). ‡All data are reported as incidence rates per 100 patient-years (95% CI).
CI=confidence interval; IFN β-1a=interferon beta-1a; MS=multiple sclerosis; OCR=ocrelizumab.
Genentech, data on file.
Page 34
6/5/2018
34
© 2018 Genentech, Inc. All rights reserved.
Fatalities summary: Post-marketing experience
■ The number of post-marketing patients exposed to OCR is based on estimated total
number of vials sold, as well as US claims data
■ Overall exposure is calculated in patient-years on OCR
■ Fatalities based on reports in the Roche safety database with patients suffering from
relapsing and progressive multiple sclerosis treated with OCR post-marketing in the
designated market period. There was no pattern observed*
*The causes of the post-marketing fatalities are as follows: Unknown cause (n=21), aspiration pneumonia (n=2), myocardial infarction (n=2), sepsis (n=2), urosepsis (n=2), cardiac disord
er (n=1), brain herniation (n=1), pulmonary embolism (n=1), opioid overdose (n=1), sudden death (n=1), acute kidney injury (n=1), cardiogenic shock with circulatory collapse and urinary
tract infection (n=1), epilepsy with status epilepticus (n=1), cellulitis with pneumonia, sepsis and urinary tract infection (n=1), asthenia with chest paint, pyrexia, and decreased appetite (n
=1), cerebral hemorrhage (n=1), influenza (n=1), lung cancer with metastases to bone and metastases to CNS (n=1), acute respiratory failure with urosepsis (n=1), respiratory failure (n=
1). †Two reports were invalidated after March 17, 2018. Reported causes of death for these patients were unknown (n=1) and respiratory failure (n=1). ‡Expressed per 100 patient-years.
CI=confidence interval; CNS=central nervous system; MS=multiple sclerosis; OCR=ocrelizumab.
Genentech, data on file.
67
Market period
Estimated patients
on OCR by end
of period
Exposure
patient-years
Fatalities
(n) Crude
incidence rate‡ 95% CI
Apr 2017 –
March 17, 2018 ~37,000 15,682 44† 0.2806
0.2039,
0.3766
© 2018 Genentech, Inc. All rights reserved.
Fatalities summary: Post-marketing setting
■ >40,000 patients have been treated with ocrelizumab as of March 17, 2018, including >37,000
in the post-marketing setting outside of clinical trials1
■ In the post-marketing setting, the incidence rate of fatalities was 0.2806 per 100 patient-years during
the period April 2017 to March 17, 2018
■ The FDA-approved prescribing information2 remains the primary source for known and potential risks
associated with ocrelizumab for the treatment of MS
■ A total of 49 fatalities have been reported outside of clinical trials from April 2017-March 31, 2018.
• 44 fatalities were reported outside of clinical trials from April 2017-March 17, 2018. Two of those reports were
subsequently invalidated‡
• 7 additional fatalities were reported after March 17th and through March 31, 2018.
■ No pattern was observed.
■ 26 fatalities were reported between January 1 and March 31, 20181
• Female (n=17) and male (n=9)1
• MS (n=7), RMS (n=4), PMS (n=3), PPMS (n=6), and RRMS (n=6)1
• Causes of death included: unknown cause (n=15), urosepsis (n=2), aspiration pneumonia (n=1),
cellulitis/pneumonia/UTI sepsis (n=1), influenza (n=1), intracerebral hemorrhage (n=1), metastatic liver
cancer (n=1), metastatic lung cancer (n=1), suicide (n=1), heart attack (n=1), and myocardial infarction
(n=1)1,*†
*Some investigations remain ongoing and information may be subject to change; MS type and cause of death were as reported verbatim by the reporter.1
†Per regulation,3 all cases of unknown or uncaptured causality are reported as ocrelizumab-related. ‡Patient did not receive Roche drug
FDA=US Food and Drug Administration; MS=multiple sclerosis; PMS=progressive multiple sclerosis; PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis; RR
MS=relapsing-remitting multiple sclerosis; UTI=urinary tract infection.
1. Genentech, data on file; 2. Ocrevus® [prescribing information]. South San Francisco, CA: Genentech, Inc, a Member of the Roche Group; March 2017; 3. US Food & Drug Administr
ation. CFR — Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80. Accessed November 2017.
68
Page 35
6/5/2018
35
© 2018 Genentech, Inc. All rights reserved.
Fatalities summary: All settings
■ Published estimates of the mortality rate in the MS population range from 0.37 per 100
patient-years2 to 0.9 per 100 patient-years3 based on an observational study in France
(n=27,603)2 and a retrospective study in the US (30,402 MS patients from the
OptumInsight Research database)3
■ The incidence rates of fatalities are derived from varied sources and are intended to
provide context. Confounding factors that may influence mortality have not been
accounted for and, therefore, no direct comparisons should be made. Such factors may
include, but are not limited to, type of MS, age, gender, disease duration, geographical
region, population size, drug exposure, comorbid conditions, treatment history, and
duration of follow-up
69
*Incidence rate during the controlled treatment period in patients randomized to OCR. †Includes all patients exposed to ocrelizumab in the global and US MS clinical trials except Ensemble; excludes patients in compassionate use program ‡April 2017 to March 17, 2018.
MS=multiple sclerosis; OCR=ocrelizumab; US=United States.
1. Genentech, data on file; 2. Leray E, et al. PLoS One 2015;10(7):e0132033; 3. Goodin DS, et al. PLoS One 2014;9(8):e105207.
Phase 3 OPERA I/II
trials*
Phase 3
ORATORIO trial*
All OCR MS
clinical trials†
Post-marketing
setting‡
Incidence rate per
100-patient years
in OCR-treated
patients1
0.07 0.25 0.169 0.2806
© 2018 Genentech, Inc. All rights reserved.
Mortality in patients with MS: French observational study
■ A French, multicenter, observational study evaluated 27,603 patients enrolled in the EDMUS
database*. The mortality rate was 0.37 (95% CI 0.36–0.39) per 100 patient-years (1,569 deaths)
■ Patients with progressive onset of MS had higher mortality rates compared with patients with
relapsing onset (0.73 [95% CI 0.67–0.81] per 100 patient-years vs 0.32 [95% CI 0.30–0.33] per 100
patient-years, respectively)
*The EDMUS database captured demographic and longitudinal clinical data for MS patients. For this study, EDMUS was linked to two national registers
(Répertoire national d'identification des personnes physiques [RNIPP] and the national death register [INSERM-CepiDc]) in order to ascertain death and causes of death.
CI=confidence interval; EDMUS=European Database for Multiple Sclerosis; MS=multiple sclerosis.
Leray E, et al. PLoS One 2015;10(7):e0132033.
70
Kaplan-Meier estimated survival curves in patients with MS
(observed) and the general French population (expected)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70
Years from MS clinical onset
Su
rviv
al
pro
ba
bilit
y (
%)
Observed survival
Expected survival
Page 36
6/5/2018
36
© 2018 Genentech, Inc. All rights reserved.
Mortality in patients with MS: US retrospective study
■ A US retrospective study enrolled 30,402 patients with MS and 89,818 non-MS
comparators* from the OptumInsight Research healthcare claims database
■ Cause of death information was obtained from death certificates
■ The difference in mortality rates for MS patients and non-MS comparators was primarily
due to infections, cardiovascular causes, and pulmonary problems
*MS and non-MS comparators were matched based on age/residence at index year and gender.
CI=confidence interval; MS=multiple sclerosis; US=United States.
Goodin DS, et al. PLoS One 2014;9(8):e105207.
71
Patients with MS Non-MS controls
Overall mortality rate per
100-patient years (95% CI)1 0.9 (0.86–0.95) 0.45 (0.43–0.46)
Number of deaths 1,579 2,332
© 2018 Genentech, Inc. All rights reserved.
Additional Details Regarding Fatalities
January–March 2018 Reports
Page 37
6/5/2018
37
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 1 of 4)
AERS
identifier
Gender,
age (y)
MS
diagnosis
OCR
infusions
Time between
last OCR
infusion and fatality
Cause of death as
reported to FDA Additional information
2053832 F, NR RRMS 2 48 d Unk Prior fingolimod; death
believed to be suicide
2053170 F, 68 RRMS 2 21 d Unk Prior GA, dimethyl
fumarate
2051610 M, 51 MS Unk Unk Cellulitis, pneumonia,
and UTI sepsis
Prior NTZ
1959821 M, 69 RRMS 2 59 d Unk Death secondary
to serious UTI
2055539 F, 55 PMS 2 99 d Aspiration pneumonia Prior IFN β-1a,
dimethyl fumarate
2059001 F, 55 RMS 1† 30 d Metastatic liver cancer Prior GA
2058077 F, 59 PMS 2 >81 d Unk Prior GA, NTZ
2059852 F, 35 RRMS 2 ≥22 d Intracerebral
hemorrhage left frontal
and parietal cortex
Prior IFN β-1b,
pulse IV MP, and
plasmapheresis; autopsy
done
*For January to March 2018; reported by physician unless otherwise noted. †One 300 mg infusion.
AERS=adverse event reporting system; d=days; F=female; FDA=US Food and Drug Administration; GA=glatiramer acetate; IFN β-1a=interferon beta-1a;
IFN β-1b=interferon beta-1b; IV=intravenous; M=male; MP=methylprednisolone; MS=multiple sclerosis; NR=not reported; NTZ=natalizumab; OCR=ocrelizumab; PMS=progressive multiple scl
erosis; RMS=relapsing multiple sclerosis; RRMS=relapsing-remitting multiple sclerosis; Unk=unknown; UTI=urinary tract infection; y=years.
Genentech, data on file.
73
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 2 of 4)
AERS
identifier
Gender,
age (y)
MS
diagnosis
OCR
infusions
Time between
last OCR
infusion and fatality
Cause of death as
reported to FDA Additional information
2062369 M, 70 PMS 2 88 d Unk Case reported by nurse;
prior IFN β-1a, IFN β-1b,
and GA
2063857 F, 43 PPMS 2 Unk Unk Prior IFN β-1a;
autopsy done
2066961 F, 49 MS 2 >150 d Influenza Past medical
history unknown
2068341 M, 67 MS Unk Unk Urosepsis Past medical
history unknown
2070864 M, 81 PPMS 2 80 d Metastatic lung
cancer
Case reported by
nurse; prior IFN β-1a,
mitoxantrone plus IFN
β-1a combination, MTX, and
mycophenolate mofetil
2073386 F, 45 RRMS 2 158 d Unk Prior GA and fingolimod
*For January to March 2018; reported by physician unless otherwise noted.
AERS=adverse event reporting system; d=days; F=female; FDA=US Food and Drug Administration; GA=glatiramer acetate; IFN β-1a=interferon beta-1a;
IFN β-1b=interferon beta-1b; M=male; MS=multiple sclerosis; MTX=methotrexate; OCR=ocrelizumab; PMS=progressive multiple sclerosis; PPMS=primary progressive multiple sclerosis;
RRMS=relapsing-remitting multiple sclerosis; Unk=unknown; y=years.
Genentech, data on file.
74
Page 38
6/5/2018
38
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 3 of 4)
AERS
identifier
Gender,
age (y)
MS
diagnosis
OCR
infusions
Time between
last OCR
infusion and fatality
Cause of death as
reported to FDA
Additional
information
2074292 F, 62 PPMS 2 >153 d Unk Prior IFN β-1b and
GA
2078616 F, approx. 64 MS Unk Unk Unk Reported by friend of
patient; past medical
history unknown
2079460 F, approx. 71 RMS Unk Unk Unk Past medical history
unknown
2080264 F, 57 PPMS 2 32 d Myocardial infarction Reported by a nurse;
prior GA
2080272 M, 28 PPMS 2 10 d Urosepsis secondary
to bladder infection
Reported by a nurse
2089979 M, 65 MS Unk Unk Unk Prior IFN β-1b
*For January to March 2018; reported by physician unless otherwise noted.
AERS=adverse event reporting system; d=days; F=female; FDA=US Food and Drug Administration; GA=glatiramer acetate; IFN β-1b=interferon beta-1b; M=male; MS=multiple sclerosis
; OCR=ocrelizumab; PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis; Unk=unknown; y=years.
Genentech, data on file.
75
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 4 of 4)
AERS identifier
Gender,
age (y)
MS
diagnosis
OCR
infusions
Time between
last OCR
infusion and fatality
Cause of death as
reported to FDA
2092457 F, 64 MS 2 9 d Unk
2094528 F, 70 MS 1 3 d Unk
2096961 M, 57 RRMS Unk Unk Suicide
2097002 M, 50 RMS 2 >5 days Heart attack
2097115 F, 36 RMS 2 44 d Unk
2093565 F, 62 PPMS 2 79 d Unk
*For January to March 2018; reported by physician unless otherwise noted.
AERS=adverse event reporting system; d=days; F=female; FDA=US Food and Drug Administration; M=male; MS=multiple sclerosis; OCR=ocrelizumab; PPMS=primary progressive mult
iple sclerosis; RMS=relapsing multiple sclerosis; RRMS=relapsing-remitting multiple sclerosis Unk=unknown; y=years.
Genentech, data on file.
76
Page 39
6/5/2018
39
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 1 of 7)
AERS
identifier Comment
2053832 A female patient with RRMS and past medical history significant for depression and prior treatment with
fingolimod received ocrelizumab in October 2017, with the day 15 infusion being administered on November 13,
2017. Patient tolerated infusions well without any changes in vital signs. The patient died on December 31,
2017, with cause of death unknown but believed by physician to be suicide and unrelated to ocrelizumab.
2053170 A 68-year-old female with RRMS with an initial EDSS of 2 and past medical history significant for sarcoidosis,
IBS, hypertension, hypersensitivity lung disease, prediabetes, psoriasis, COPD and pulmonary nodules, and on
multiple concomitant mediations, received prior MS medications of glatiramer acetate and dimethyl fumarate.
Patient had been administered two infusions of ocrelizumab: one on June 24, 2017, and the other on July 10,
2017. She tolerated both well. Patient passed away on July 31, 2017, from unknown cause. Provider stated it
was unknown whether death was related to ocrelizumab due to comorbid conditions.
2051610 A 51-year-old male patient with MS on hospice care, who initiated ocrelizumab on an unknown date, passed
away on December 16, 2017. Prior MS treatment included natalizumab. Cause of death is reported as cellulitis,
pneumonia, and UTI sepsis. Autopsy was not performed. Provider believes death is not related to ocrelizumab.
1959821 A 69-year-old male with RRMS (EDSS of 6) had a past medical history significant for multiple UTIs, Merkel cell
carcinoma of the neck (treated with chemotherapy), myocardial infarction in 2010, and three strokes: two in 2013
and one in 2014. Patient received ocrelizumab June 27, 2017, and September 11, 2017. Patient developed a
UTI after initial infusion, which led to delay between infusions. Patient passed away on November 9, 2017,
secondary to a serious UTI. Causality was assessed as unknown.
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; COPD=chronic obstructive pulmonary disease; EDSS=Expanded Disability Status Scale; IBS=inflammatory bowel syndrome;
MS=multiple sclerosis; RRMS=relapsing-remitting multiple sclerosis; UTI=urinary tract infection.
Genentech, data on file.
77
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 2 of 7)
AERS
identifier Comment
2055539 A 55-year-old female patient with progressive MS requiring wheelchair use had prior MS medications of IFN β-
1a and dimethyl fumarate. Patient received two infusions of ocrelizumab on September 18, 2017, and October 3,
2017. Of note, provider mentioned that, prior to the ocrelizumab infusion, she was only able to walk 10–20 feet,
and several weeks after her last infusion, she was walking up to 40 feet. Patient passed away due to aspiration
pneumonia on January 8, 2018. No autopsy was performed. Causality between ocrelizumab and death was
reported as possibly related.
2059001 A 55-year-old female patient with RMS and previously on glatiramer acetate had one infusion of ocrelizumab on
July 7, 2017. The patient passed away on August 6, 2017. Cause of death was reported as metastatic liver
cancer. The physician believes cancer and death are not related to ocrelizumab.
2058077 A 59-year-old female with progressive MS (wheelchair-bound) had a past medical history significant for
prediabetes, hypertension, recurrent UTIs, bed sores, and recurrent respiratory infections. Prior MS medications
were glatiramer acetate and natalizumab. Natalizumab was discontinued in June 2017 due to JCV+ (index of
0.42). Patient had two infusions of ocrelizumab on July 26, 2017, and August 11, 2017. Patient tolerated
infusions without issue. Patient passed away in November of unknown cause. Provider believes that death is
unrelated to ocrelizumab.
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; IFN β-1a=interferon beta-1a; JCV=John Cunningham virus; MS=multiple sclerosis; RMS=relapsing multiple sclerosis; UTI=urinary tract infection.
Genentech, data on file.
78
Page 40
6/5/2018
40
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 3 of 7)
AERS
identifier Comment
2059852 A 35-year-old female patient diagnosed with RRMS for the past 12 years had prior MS medications of IFN β-1b,
pulse intravenous methylprednisolone, and plasmapheresis. Patient was also on multiple concomitant pain
medications. Patient received two infusions of ocrelizumab in August and September 2017. On October 16,
2017, she was reported as receiving day 4 of her usual 5-day IVIG. On October 17, 2017, she did not make her
appointment for day 5 of IVIG, but did report severe headache. She was admitted to hospital on October 18,
2017, due to nausea, vomiting, photophobia, and neck stiffness. On October 22, 2017, she died in hospital due
to intracerebral hemorrhage of the left frontal and parietal cortex. The physician reviewed the autopsy and
determined the death to be due to IVIG and to be not associated with ocrelizumab.
2062369 A 70-year-old male with progressive MS, wheelchair-bound for the past 8 years, received prior MS medications
of IFN β-1a, IFN β-1b, and glatiramer acetate. Past medical history included hip replacement, paroxysmal atrial
fibrillation, colostomy, suprapubic urostomy, and sacral ulcers. Patient was also on multiple symptom-controlling
concomitant medications. Patient had two infusions of ocrelizumab on August 7, 2017, and September 7, 2017.
Patient contracted pneumonia between first and second infusions and passed away on December 4, 2017.
Provider believes death is not related to ocrelizumab.
2063857 A 43-year-old female with PPMS and an EDSS of 9, prior MS medications of IFN β-1a, and past medical history
significant for UTIs, received two infusions of ocrelizumab on December 26, 2017, and January 9, 2018. She
passed away on an unknown date due to an unknown cause. The reporting physician knew very few details
surrounding the death. It was mentioned that “she might have had a pulmonary embolism because she did not
move very much.” Autopsy was performed, and results would be available in 6–8 weeks. The physician
assessed death as possibly related to ocrelizumab.
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; EDSS=Expanded Disability Status Scale; IFN β-1a=interferon beta-1a; IFN β-1b=interferon beta-1b; IVIG=intravenous immunoglobulin;
MS=multiple sclerosis; PPMS=primary progressive multiple sclerosis; RRMS=relapsing-remitting multiple sclerosis; UTI=urinary tract infection.
Genentech, data on file.
79
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 4 of 7)
AERS
identifier Comment
2066961 A 49 year old female with MS (bedridden) started ocrelizumab on an unknown date and received a second
infusion on August 7, 2017. On December 30, 2017 she developed pneumonia and influenza. Ocrelizumab was
discontinued due to the adverse events. On January 4, 2018, the pneumonia resolved. On an unspecified date,
she passed away with influenza. Physician assessed that the pneumonia was related to ocrelizumab but
influenza was not related.
2068341 A 67-year-old male with MS with unknown past medical history or concomitant medications started ocrelizumab
on an unknown date. The patient was diagnosed with a bladder infection on an unknown date. On December 2,
2017, he was diagnosed with urosepsis; he died on December 11, 2017. Causality was assessed as unknown
by the physician.
2070864 An 81-year-old male with PPMS (EDSS of 8.0) with past medical history significant for an approximately 50-year
history of smoking, subdural hematoma after a fall in July 2015, and Alzheimer's disease previously received IFN
β-1a, mitoxantrone, and methotrexate. The patient received two infusions of ocrelizumab on October 16, 2017,
and October 30, 2017. The patient was diagnosed with metastatic lung cancer on January 5, 2018, and passed
away secondary to this on January 18, 2018. The provider does not believe that the cancer or death were
related to ocrelizumab.
2073386 A 45-year-old female patient diagnosed with RRMS and had prior MS medications of glatiramer acetate and
fingolimod was wheelchair-bound, had difficulty communicating, and was on palliative care. She was given two
infusions of ocrelizumab on August 18, 2017, and September 1, 2017. Patient died due to an unknown cause on
February 6, 2018. The physician assessed that death was not related to ocrelizumab.
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; EDSS=Expanded Disability Status Scale; IFN β-1a=interferon beta-1a; MS=multiple sclerosis; PPMS=primary progressive multiple sclerosis; RR
MS=relapsing-remitting multiple sclerosis.
Genentech, data on file.
80
Page 41
6/5/2018
41
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 5 of 7)
AERS
identifier Comment
2074292 A 62-year-old chronically ill female with a 30-year history of PPMS was nonambulatory and had a past medical
history significant for decubitus ulcers and pneumonia. Past drugs included IFN β-1b and glatiramer acetate. In
June 2017, the patient started ocrelizumab and received the second infusion in July 2017. It was reported that
she progressively went downhill following the infusion. In January 2018, patient passed away of unknown cause.
Causality was assessed as unknown.
2078616 An approximately 64-year-old female patient with unknown medical history and concomitant medications started
ocrelizumab on an unknown date. The patient died due to unknown cause on an unknown date.
2079460 An approximately 71-year-old female patient with RMS and unknown medical history, concurrent conditions,
concomitant medications, or past drugs started ocrelizumab on an unknown date. On January 14, 2018, she died
due to unknown cause. The reporter did not state the causality between death and ocrelizumab.
2080264 A 57-year-old female patient diagnosed with PPMS had baseline severe cognitive issues (nonverbal) and was
cared for by family. Past medical history included seizures. Prior MS medications included glatiramer acetate.
Patient started ocrelizumab on December 18, 2017, and received her second infusion on January 2, 2018. On
February 3, 2018, the patient passed away secondary to a myocardial infarction. The nurse assessed the
myocardial infarction as not related to ocrelizumab.
81
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; IFN β-1b=interferon beta-1b; MS=multiple sclerosis; PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis.
Genentech, data on file.
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 6 of 7)
AERS
identifier Comment
2080272 A 28-year-old male with PPMS and a past medical history of chronic bladder infections and UTIs and multiple
concomitant pain, antianxiety, and antispasmodic medications received ocrelizumab in June 2017 and January
23, 2018. Patient was diagnosed with bladder infection and developed urosepsis on January 31, 2018. Patient
died on February 2, 2018. Nurse believed that the patient's ability to fight the infection might have been
compromised, but causality between death and ocrelizumab is reported as unknown.
2089979 A 65-year-old male with MS previously on IFN β-1b started ocrelizumab in June 2017. The patient passed away
on March 5, 2018. Cause of death is unknown. Causality was not reported.
2092457 A 64-year-old female patient with MS (EDSS 7.0) with past medical history significant for diabetes, hypertension,
and tobacco received ocrelizumab on August 7, 2017 and August 22, 2017. Patient passed away on August 31,
2017, due to unknown cause. The physician assessed the causality as unknown.
2094528 An approximately 70-year-old female with MS passed away 3 days after her first infusion of ocrelizumab.
Contact with prescriber has been unsuccessful thus far and Roche Genentech continues to try and obtain further
information about this case.
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; EDSS=Expanded Disability Status Scale; IFN β-1b=interferon beta-1b; MS=multiple sclerosis; PPMS=primary progressive multiple sclerosis; UTI
=urinary tract infection.
Genentech, data on file.
82
Page 42
6/5/2018
42
© 2018 Genentech, Inc. All rights reserved.
Fatalities: Spontaneous reports in post-approval setting* (slide 7 of 7)
AERS
identifier Comment
2096961 An approximately 57-year-old male with RRMS diagnosed in December 2017 (tumefactive, ambulatory with mild
weakness) started ocrelizumab on an unknown date. Patient passed away due to suicide. Causality was stated
as unrelated.
2097002 An approximately 50-year-old male with RMS (left-sided hemiparesis) and past medical history significant for
diabetes, obesity, and atrial fibrillation on dabigatran etexilate, digoxin, diltiazem, lisinopril, metformin, and
metoprolol received ocrelizumab on July 12, 2017, and July 26, 2017. Patient passed away from a severe heart
attack in August 2017. Autopsy is pending. Causality was not reported.
2097115 A 36-year-old female with RMS (EDSS of 2) and past medical history significant for hyperlipidemia received
ocrelizumab on January 17, 2018, and February 5, 2018. On March 21, 2018, the patient had shortness of
breath, became diaphoretic, and collapsed at home. Patient could not be revived. Cause of death is unknown.
Autopsy is pending.
2093565 A 62 year old female patient with PPMS being treated with ocrelizumab received a 300 mg ocrelizumab infusion
on October 29, 2017. The patient passed away on January 16, 2018. Cause of death is unknown and causality
was not reported.
*For January to March 2018; additional information is still being sought on some of these reports.
AERS=adverse event reporting system; EDSS=Expanded Disability Status Scale; MS=multiple sclerosis; RMS=relapsing multiple sclerosis; RRMS=relapsing-remitting multiple sclerosis;
UTI=urinary tract infection.
Genentech, data on file.
83